Pharmaceuticals & HealthcareIndia to Belgium
Belgium punches far above its weight in European pharmaceuticals. Despite a population of just 11.5 million, Belgium is the EU's second-largest pharmaceutical exporter by value and hosts the European operations of major global firms including Johnson & Johnson (Janssen), UCB, Galapagos, and numerous biotech companies. Brussels' proximity to EU institutions — the European Commission, Council, and Parliament — makes Belgium the de facto capital of EU pharmaceutical policy and lobbying. FAMHP (Federal Agency for Medicines and Health Products) is the national regulatory authority, and Belgium's reimbursement system through INAMI/RIZIV offers structured pathways for generics and biosimilars. For Indian exporters, Belgium represents both a direct market opportunity and an unparalleled regulatory and policy hub. The FTA's tariff elimination of up to 11% benefits both finished product imports and Belgium's significant CDMO sector sourcing Indian APIs.
Last updated: 2026-03-01 · Eurostat COMEXT, FAMHP (FAGG/AFMPS), EMA, DGFT India, Pharmexcil, INAMI/RIZIV, pharma.be
FTA Impact Analysis
Up to 11% tariff elimination — Belgium as EU pharmaceutical policy capital and CDMO hub
Before / After
Pre-FTA: MFN duties of 0–6.5% on APIs and 4–11% on finished pharmaceutical products. Post-FTA: Zero duty on all covered pharmaceutical tariff lines, benefiting both direct Belgian market and CDMO/contract manufacturing operations.
Phase-Out Timeline
65% of pharmaceutical tariff lines go to zero on entry into force. Remaining medical device and biologic input lines phased over 3–7 years.
Medicaments in measured doses, put up for retail sale
Ephedrine and its salts in dosage form
Other alkaloids (bulk APIs) not elsewhere specified
Other vitamins and derivatives (bulk, unmixed)
Malaria diagnostic test kits
Dental drill engines
Apparatus based on the use of alpha, beta, or gamma radiations for medical use
Waste pharmaceuticals (for safe disposal/processing)
For Indian Exporters
Belgium's CDMO sector (Thermo Fisher in Geel, Lonza in various sites, numerous smaller CDMOs) sources significant API volumes from India. Zero-duty API imports reduce production costs for Belgian CDMOs, making them more competitive globally and incentivizing increased Indian sourcing. For finished dosage form exporters, Belgium's small but well-structured healthcare market offers a manageable entry point, and Brussels-based operations provide proximity to EU regulatory and policy institutions — invaluable for firms building pan-EU strategies.
For European Buyers
Belgian hospital pharmacists (especially at major university hospitals: UZ Leuven, ULB Erasme, UZ Gent) can leverage FTA tariff reductions on Indian generics and biosimilars. Belgian CDMOs and contract manufacturers benefit from zero-duty Indian API imports. Pharmaceutical distributors (Febelco, Cerp, Multipharma) should evaluate expanded Indian-origin generic portfolios given the INAMI/RIZIV push for generic substitution.
FAMHP authorization is mandatory. Belgium's trilingual requirements (Dutch, French, German) for labelling and patient information leaflets add complexity and cost. INAMI/RIZIV reimbursement is separate from marketing authorization — budget impact analysis is required. Rules of origin apply for FTA preference claims.
Market Intelligence
Bilateral Trade Volume (€M)
India-Belgium pharmaceutical trade has grown at approximately 10.4% CAGR, driven by Belgium's unique position as both a consumption market and a pharmaceutical manufacturing/re-export hub. Belgium's domestic pharmaceutical market is approximately €7.5 billion, but the country's pharmaceutical exports exceed €65 billion — reflecting its role as a production base for multinationals. Generic penetration in Belgium has historically lagged behind northern European peers (currently ~35% by volume) but is rising as the government implements cost-containment measures. The INAMI/RIZIV low-cost medicine policy (which requires pharmacists to propose the cheapest available generic/biosimilar) is driving increased demand for Indian-origin products.
Top Product Categories
Key Indian Production Clusters
Hyderabad
Primary API supply hub for Belgian CDMO operations. Multiple facilities maintain FAMHP-registered status. Dr. Reddy's and Laurus Labs have dedicated Belgium-facing production
Mumbai
Cipla and Glenmark maintain Belgian distribution arrangements coordinated from Mumbai. Regulatory affairs offices managing FAMHP dossiers
Ahmedabad
Cadila Healthcare (Zydus) supplies Belgian market through its European subsidiary. Torrent Pharma has FAMHP-authorized product lines
Brussels
EU institutional capital — European Commission (DG SANTE, DG GROW), European Parliament health committee, industry associations (EFPIA, Medicines for Europe). Indian firms maintain Brussels policy offices for EU regulatory intelligence
Flanders (Geel, Beerse, Mechelen)
Belgium's pharma heartland — Janssen (J&J) in Beerse, Thermo Fisher CDMO in Geel, numerous biotech firms. Heavy API sourcing from India
Wallonia (Charleroi, Liège)
GSK Biologicals (vaccines) in Wavre, UCB in Braine-l'Alleud. Growing CDMO cluster with Indian API supply chains
Buyer Profiles
Belgian pharmaceutical buyers span several categories: (1) Hospital pharmacy departments at university hospitals (UZ Leuven, ULB, UZ Gent, CHU Liège) and hospital networks (GZA, Jessa); (2) Wholesale distributors and cooperatives (Febelco — largest Belgian pharma wholesaler, Cerp, DA Pharma); (3) Pharmacy chains and cooperatives (Multipharma — 240+ pharmacies, Medi-Market, independent pharmacy cooperatives); (4) CDMO/CMO operations (Thermo Fisher, Lonza, Catalent Belgian sites) sourcing APIs; (5) Multinational procurement offices based in Brussels (many EU-wide pharma procurement decisions are made from Belgian headquarters). Belgium's small size means personal relationships and local presence matter disproportionately.
Competitive Landscape
Belgium's pharmaceutical market is dominated by multinational innovators (Janssen, UCB, Pfizer, Sanofi) given the country's role as a pharma manufacturing base. The generics segment is smaller but growing, with Sandoz, Teva, Mylan/Viatris, and EG (Stada group — Indian-owned) as leading players. Indian firms' direct presence in Belgium is more limited than in Germany or the Netherlands, but Aurobindo, Accord Healthcare (Intas), and Sun Pharma distribute through Belgian partners. The main competitive opportunity lies in API supply to Belgian CDMOs — Belgium's €65B+ pharmaceutical export industry requires massive API input, and Indian suppliers are already significant but can grow further with FTA tariff advantages.
Compliance & Regulatory Guide
Mandatory Requirements
FAMHP Marketing Authorization
mandatoryAll medicinal products require marketing authorization via national, decentralized, mutual recognition, or centralized procedure
Enforced by: FAMHP (Federal Agency for Medicines and Health Products / AFMPS / FAGG)
FAMHP has trilingual requirements — dossier correspondence in English is accepted, but labelling and PIL must be in Dutch, French, and German. Average generic MA timeline: 180–210 days via DCP. FAMHP is a respected CMS and occasional RMS in decentralized procedures.
EU GMP Certification
mandatoryManufacturing sites must hold valid EU GMP certificates
Enforced by: FAMHP Inspectorate
FAMHP conducts non-EU manufacturing site inspections and participates in EU joint inspections. Belgian inspectors have a reputation for thoroughness on data integrity and environmental monitoring. Ensure your clean room validation data is current.
INAMI/RIZIV Reimbursement
mandatoryProducts must be listed for reimbursement through Belgium's compulsory health insurance system to achieve meaningful market access
Enforced by: INAMI/RIZIV (Institut National d'Assurance Maladie-Invalidité / Rijksinstituut voor Ziekte- en Invaliditeitsverzekering)
Generic reimbursement in Belgium follows a structured price reduction from originator: 51.52% reduction on Day 1 for oral solids. The CTG (Commission de Transparence / Commissie Tegemoetkoming Geneesmiddelen) evaluates therapeutic value. Budget impact analysis is required for hospital products.
Falsified Medicines Directive (FMD) / BeMVO
mandatorySerialization and tamper-evident packaging for prescription medicines in Belgium
Enforced by: BeMVO (Belgian Medicines Verification Organisation)
Belgium has full FMD implementation. Pharmacies and hospitals verify every prescription pack through BeMVO. Ensure your serialization system integrates with the Belgian national repository.
Trilingual Labelling Requirement
mandatoryAll product labelling, package leaflets, and patient information must be in Dutch, French, and German
Enforced by: FAMHP
This is a non-negotiable requirement and a common stumbling block for new market entrants. Engage certified pharmaceutical translators — machine translation is not acceptable for PIL. Some firms use tri-fold leaflets or booklet labels to accommodate three languages.
Belgian Pharmacovigilance System
mandatoryPost-market safety monitoring through the Belgian PV system
Enforced by: FAMHP
Belgium requires adverse event reporting through the FAMHP online portal. A local or EU-based QPPV is required. Belgian PV requirements align with EU GVP but have specific national annexes for reporting timelines.
Belgian Sunshine Act (Transparantie / Transparence)
mandatoryDisclosure of transfers of value from pharma companies to Belgian healthcare professionals
Enforced by: FAMHP / Mdeon ethics platform
Belgium has one of Europe's most stringent transparency regimes. All transfers of value above €1 must be disclosed. The Mdeon platform pre-approves scientific events and grants. Non-compliance carries significant reputational risk in Belgium's small pharma community.
Commercially Expected
FOST Plus / Extended Producer Responsibility
expectedPackaging waste management obligations for pharmaceutical packaging in Belgium
Enforced by: FOST Plus / OVAM (Flanders) / OWD (Wallonia)
Register with FOST Plus and declare pharmaceutical packaging volumes. Belgium has among the highest packaging recycling rates in Europe — use recyclable materials to minimize green dot contributions.
Country-Specific Requirements
Belgium's pharmaceutical regulatory environment reflects the country's trilingual federal structure. FAMHP operates in Dutch, French, and German, and all patient-facing materials must be available in all three languages — a requirement that adds complexity and cost compared to single-language markets. Belgium's proximity to EU institutions means that Belgian regulatory positions often influence EU-wide pharmaceutical policy, and early engagement in Brussels can provide strategic intelligence on regulatory trends. The INAMI/RIZIV reimbursement system requires a formal application process with budget impact analysis, and the Belgian government has been progressively tightening generic pricing requirements through periodic royal decrees. Belgium's unique 'kiwi model' procurement (centralized tendering for certain hospital products) was pioneered here and has been adopted by other EU countries. For Indian firms, Belgium offers a small but high-value direct market combined with unmatched proximity to EU decision-making and significant CDMO/CMO demand for APIs.
Common Pitfalls
Critical pitfalls for Indian pharma exporters in Belgium: (1) Trilingual labelling and PIL — underestimating the cost and timeline of certified pharmaceutical translation in Dutch, French, and German; (2) Assuming Brussels office = EU market access — Belgian MA and reimbursement are separate national processes; (3) Belgium's transparency regime (Mdeon) is among Europe's strictest — any engagement with Belgian HCPs requires pre-approval; (4) INAMI/RIZIV generic price reductions are steeper than many EU markets (51.52% Day 1 reduction) — model profitability carefully; (5) Belgium's small market size means volume per product is limited — the strategic value is in EU-wide positioning, not Belgian revenue alone; (6) Not leveraging Belgium's CDMO demand — selling APIs to Belgian contract manufacturers is often more profitable than building a finished dosage presence.
Logistics & Practical Information
Shipping Routes
Primary sea route: JNPT / Mundra → Antwerp (Europe's second-largest port, 20–24 days via Suez Canal). Air freight: Mumbai / Hyderabad → Brussels Airport (BRU — major pharma cargo hub with dedicated GDP-certified handling) or Liège Airport (LGG — Europe's 6th largest cargo airport). Antwerp and Brussels together provide comprehensive sea and air access.
Transit Times
Sea freight: 20–24 days JNPT to Antwerp. Air freight: 9–12 hours to Brussels BRU. Door-to-door: 26–32 days (sea) or 3–5 days (air). Belgium's compact geography means inland transit from port/airport to final destination is typically same-day — Antwerp to Brussels is 45 minutes, to Flanders pharma cluster 30 minutes.
Ports of Entry
Antwerp (Europe's second-largest container port, extensive cold chain and pharma-grade facilities), Brussels Airport (BRU — top-5 European pharma air cargo hub with dedicated Pharma.Aero certified handling), Liège Airport (major cargo hub for express and charter pharma shipments), Zeebrugge (specialized port for certain bulk cargo routes).
Common Incoterms
CIP Antwerp or CIP Brussels Airport are standard. DAP Belgian warehouse for firms with Benelux distribution operations (many logistics providers in Antwerp or Mechelen area offer GDP-certified pharma warehousing). FCA Indian port for API shipments to Belgian CDMO/CMO buyers. DDP is used by larger Indian firms with established Belgian subsidiaries.
Customs Clearance
Belgian customs (FOD Financiën / SPF Finances) is highly efficient — electronic declarations via PLDA (Paperless Customs and Excise) system. Belgium offers AEO certification and Single Authorization for simplified customs procedures. Pharmaceutical imports require: FAMHP marketing authorization, EU GMP certificate, batch CoA, FMD serialization confirmation, EUR.1 for FTA preference. Antwerp port has dedicated pharmaceutical inspection and release procedures. Average customs clearance: 1–2 business days for compliant shipments — among the fastest in the EU.
Documents Required
- Commercial Invoice with HS tariff classification
- Bill of Lading / Air Waybill
- Certificate of Pharmaceutical Product (CoPP) from CDSCO
- EU GMP Certificate for manufacturing site
- Batch Certificate of Analysis (CoA)
- EUR.1 Movement Certificate or origin declaration for FTA preference
- FMD serialization data upload confirmation (BeMVO)
- Trilingual labelling and package leaflet (Dutch/French/German)
- Temperature monitoring records (cold chain)
- Written Confirmation for API imports (Directive 2011/62/EU)
Payment Terms
Belgian health system payments: net 30–60 days — Belgium has strong payment discipline. Hospital procurement: net 30–45 days. Wholesale distributors: net 30 days. CDMO/CMO API purchases: net 30–45 days from delivery. Belgian payment culture is reliable and efficient — one of the best in the EU. Open account with credit insurance is standard for established relationships. New suppliers may start with confirmed LC or partial advance, transitioning to open account within 3–6 months.